FOXA1 Induces E-Cadherin Expression at the Protein Level via Suppression of Slug in Epithelial Breast Cancer Cells

Erina Anzai, Kensuke Hirata, Misato Shibazaki, Chiaki Yamada, Mariko Morii, Takuya Honda, Naoto Yamaguchi, and Noritaka Yamaguchi*

Laboratory of Molecular Cell Biology, Graduate School of Pharmaceutical Sciences, Chiba University; 1–8–1 Inohana, Chuo-ku, Chiba 260–8675, Japan.

Received April 12, 2017; accepted June 7, 2017

Epithelial-to-mesenchymal transition (EMT) is an important process during embryonic development and tumor progression by which adherent epithelial cells acquire mesenchymal properties. Forkhead box protein A1 (FOXA1) is a transcriptional regulator preferentially expressed in epithelial breast cancer cells, and its expression is lost in mesenchymal breast cancer cells. However, the implication of this biased expression of FOXA1 in breast cancer is not fully understood. In this study, we analyzed the involvement of FOXA1 in EMT progression in breast cancer, and found that stable expression of FOXA1 in the mesenchymal breast cancer MDA-MB-231 cells strongly induced the epithelial marker E-cadherin at the mRNA and protein levels. Furthermore, stable expression of FOXA1 was found to reduce the mRNA and protein expression of Slug, a repressor of E-cadherin expression. FOXA1 knockdown in the epithelial breast cancer MCF7 cells reduced E-cadherin protein expression without decreasing its mRNA expression. In addition, FOXA1 knockdown in MCF7 cells up-regulated Slug mRNA and protein expression. Notably, similar to FOXA1 knockdown, stable expression of Slug in MCF7 cells reduced E-cadherin protein expression without decreasing its mRNA expression. Taken together, these results suggest that although FOXA1 can induce E-cadherin mRNA expression, it preferentially promotes E-cadherin expression at the protein level by suppressing Slug expression in epithelial breast cancer, and that the balance of this FOXA1-Slug axis regulates EMT progression.

Key words epithelial–mesenchymal transition; E-cadherin; forkhead box protein A1; Slug; estrogen receptor-

MATERIALS AND METHODS

Plasmids Plasmids encoding FOXA1 and ERα were generated as described previously.17) cDNA encoding Slug was generated by PCR from the reverse-transcribed product of MDA-MB-231 total RNA and was subcloned into the pIRESpuro3 vector (TaKaRa, Shiga, Japan). A myc tag was added to the N-terminal cDNA of Slug.

Antibodies The following antibodies were used: FOXA1 (sc-6553) and p53 (sc-126) from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.); ERα (#8644), E-cadherin (#3195), Slug (#9585), and vimentin (#5741) from Cell Signaling Technology (Beverly, MA, U.S.A.); LC3 (PM036) from MBL (Nagoya, Japan); and actin (MAB1501) from Merck Millipore (Gyancourt, France). Horseradish peroxidase (HRP)-F(ab’), secondary antibodies were purchased from GE Healthcare (Waukesha, WI, U.S.A.).

* To whom correspondence should be addressed. e-mail: yamaguchinoritaka@chiba-u.jp

© 2017 The Pharmaceutical Society of Japan
Cells and Transfection  MCF7 and MDA-MB-231 cells were cultured in Dulbecco’s modified Eagle’s medium (Dulbecco’s modified Eagle’s medium (DMEM); Nissui, Tokyo, Japan) containing 5% fetal bovine serum. MG-132 and bafilomycin A1 were purchased from Peptide Institute (Osaka, Japan) and Cayman Chemical (Ann Arbor, MI, U.S.A.), respectively. For plasmid transfection, cells were seeded in a 35-mm (or 60-mm) culture dish and transiently transfected with 1 µg (or 3 µg) of plasmid DNA using Lipofectamine 2000 (Life Technologies, Carlsbad, CA, U.S.A.) according to the manufacturer’s instructions. To establish stable cell pools, cells were transfected with pRESPuro3 vectors and selected with puromycin (1 µg/mL) for 2 wk. Puromycin-resistant cells were used as stable cell pools. Small interfering RNA (siRNA) for FOXA1 #1 (sense: 5′-GAA CGACG CUG CAA UAC UC GCU UU CC-3′ and anti-sense: 5′-AAG GCG AGU AUU GCA GUG CU GU UUC-3′) was purchased from Life Technologies. siRNAs for FOXA1 #2 (sense: 5′-GAG AGA AAA AUA UCA CGC-3′ and anti-sense: 5′-GCU GUU GAU UUU UUC UC-3′) and luciferase (sense: 5′-GGC GUG CGU GUG GCA ACC CTT-3′) and anti-sense: 5′-GGG UUG GC A CCA GCA CCG TCT-3′) were purchased from Hokkaido System Sciences (Hokkaido, Japan). siRNAs were transfected into cells using Lipofectamine 2000 according to the manufacturer’s instructions.

Western Blotting  Western blotting was performed by enhanced chemiluminescence (Merck Millipore) as described previously.17) Whole cell lysates were prepared in sodium dodecyl enhanced chemiluminescence (Merck Millipore) as described (Life Technologies, Carlsbad, CA, U.S.A.) according to the manufacturer’s instructions. The primers used for PCR were as follows: glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 5′-GCC AGG GCT ACG GGT-3′ (antisense); E-cadherin (CDH1), 5′-CGA GAG CTA CAG GTT CAC GG-3′ (sense) and 5′-GGG TGT CGA GGA AAA AAT AGG-3′ (antisense); Snail (SNAI1), 5′-TCG GAA GCC TAA CTC ATG GA-3′ (antisense); Slug (SNAI2), 5′-TGG GAG AAG GAA TAT GTG AGC C-3′ (sense) and 5′-TGA GCC CTC AGA TT T TGG C-3′ (antisense); FOXA1 (FOXA1), 5′-GCA AT A TCT GCC CT AAA C-3′ (sense) and 5′-TAC ACA CTT TGT GAG TAC GTC-3′ (antisense). 

Intensity of chemiluminescence was measured using Quantity One software (Bio-Rad, Richmond, CA, U.S.A.). Intensity of chemiluminescence was measured using Quantity One software (Bio-Rad).

Quantitative Real-Time PCR (qPCR) Analysis  qPCR was performed as described previously.18) Briefly, total RNA was isolated from cells using RNAiso Plus (TaKaRa), and cDNA was synthesized from 0.5 µg of each RNA preparation using a ReverTra Ace qPCR RT Kit (TOYOBO, Tokyo, Japan), according to the manufacturer’s instructions. The primers used for PCR were as follows: glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 5′-ACC ACA GT C AT GCC ATC AC-3′ (sense) and 5′-TCC ACC ACC CTG TTG CTG TA-3′ (antisense); E-cadherin (CDH1), 5′-CGA GAG CTA CAG GTT CAC GG-3′ (sense) and 5′-GGG TGT CGA GGA AAA AAT AGG-3′ (antisense); Snail (SNAI1), 5′-TCG GAA GCC TAA CTC ATG GA-3′ (antisense); Slug (SNAI2), 5′-TGG GAG AAG GAA TAT GTG AGC C-3′ (sense) and 5′-TGA GCC CTC AGA TT T TGG C-3′ (antisense); FOXA1 (FOXA1), 5′-GCA AT A TCT GCC CT AAA C-3′ (sense) and 5′-TAC ACA CTT TGT GAG TAC GTC-3′ (antisense). After initial denaturation at 95°C for 1 min, PCR was performed for 40 cycles (15 at 95°C and 45 s at 60°C) by using a Thunderbird SYBR Green Polymerase Kit (TOYOBO) and an Eco Real-Time PCR System (Illumina, San Diego, CA, U.S.A.).

Immunofluorescence  Confocal and Nomarski differential-interference-contrast (DIC) images were obtained with a Fluoview FV500 confocal laser scanning microscope (Olympus, Tokyo, Japan), as described.19) In brief, cells were fixed in 4% paraformaldehyde for 20 min at room temperature and permeabilized in phosphate-buffered saline (PBS) containing 0.2% Triton X-100 and 3% bovine serum albumin. Cells were subsequently reacted with anti-Slug antibody (#9585) for 1 h, washed with PBS containing 0.1% saponin, stained with Alexa Fluor 488-conjugated secondary antibody for 1 h, and mounted with ProLong antifade reagent (Life Technologies). Nuclei were stained with TO-PRO-3 (Life Technologies).

Wound Healing Assay  Cells were seeded in a 35-mm culture dish and cultured until they reached 100% confluency. Wounds of equal width were generated in confluent cell layers using a pipette tip. Images of the wound healing process were captured with a phase-contrast microscope after the indicated periods. Invaded area, measured using the ImageJ software, was calculated as follows: percentage of invaded area=[1−(wounded area at the indicated time)/(wounded area at 0 h)]×100.

RESULTS

FOXA1 Induces E-Cadherin Expression Independently of ERα In this study, we used MCF7 cells as a model of estrogen-dependent ERα-positive epithelial breast cancer and MDA-MB-231 cells as a model of estrogen-independent ERα-negative mesenchymal breast cancer. Expression of ERα, its transcriptional partner FOXA1, and the epithelial marker E-cadherin was detected in MCF7 cells, but not in MDA-MB-231 cells (Supplementary Fig. S1A). In contrast, the mesenchymal marker Slug was expressed only in MDA-MB-231 cells. MCF7 cells showed cell–cell adhesion with cobblestone-like morphology, whereas MDA-MB-231 cells lacked cell–cell adhesion with spindle-like morphology (Supplementary Fig. S1B). Wound healing assays showed that MDA-MB-231 cells had higher motility than MCF7 cells (Supplementary Fig. SIC). These results showed that MCF7 cells exhibited characteristic of estrogen-dependent ERα-positive epithelial breast cancer, whereas MDA-MB-231 cells had those of estrogen-independent ERα-negative mesenchymal breast cancer.

Because previous studies have shown that ERα and FOXA1 are involved in E-cadherin expression,20,21) we investigated the genes important for E-cadherin expression in breast cancer cells by stable expression of each gene in MDA-MB-231 cells. Although E-cadherin expression was profoundly induced at the mRNA and protein levels by stable expression of FOXA1, ERα expression did not affect E-cadherin expression (Figs. 1A, B). We also found that Slug expression was significantly reduced at the mRNA and protein levels by stable expression of FOXA1 (Figs. 1A, B). Expression of the Slug homolog Snail was not affected by stable expression of each gene. Wound healing assays showed that FOXA1 expression significantly reduced the motility of MDA-MB-231 cells (Fig. 1C). FOXA1 expression changed spindle-like morphology into shrunk morphology in MDA-MB-231 cells (Fig. 1D). These results suggest that FOXA1, but not ERα, plays an important role in suppression of EMT in breast cancer cells via induction of E-cadherin expression and inhibition of Slug expression.

FOXA1 Suppresses Slug Expression in Breast Cancer Cells  We next analyzed the role of endogenous FOXA1 in suppression of EMT. siRNA-mediated depletion of endogenous FOXA1 caused a significant reduction in E-cadherin expression at the protein level in MCF7 cells (Figs. 2A, B). However, E-cadherin mRNA expression was slightly increased, rather
than decreased, by FOXA1 depletion (Fig. 2C). These results suggest that although FOXA1 induces E-cadherin expression in epithelial breast cancer MCF7 cells, FOXA1 does not function as a transcriptional inducer for CDH1 in these cells. Because FOXA1 has been reported to suppress Slug expression,14) we analyzed the involvement of FOXA1 in Slug expression in MCF7 cells. Knockdown of FOXA1 was found to strongly induce Slug expression at the mRNA and protein levels (Figs. 2A-C). Although Snail mRNA expression was increased by FOXA1 knockdown, this increase was very weak (Fig. 2C). These results suggest that FOXA1 mainly functions as a transcriptional repressor for Slug gene (SNAI2) in MCF7 cells. To investigate the effects of Slug on E-cadherin expression in MCF7 cells, we stably expressed Slug in these cells (Fig. 3A). Notably, similar to FOXA1-depleted MCF7 cells, Slug expression significantly suppressed E-cadherin protein level without decreasing its mRNA level in Slug-expressing cells (Figs. 3B–D). These results suggest that the reduction in E-cadherin expression is mediated by Slug in FOXA1-depleted MCF7 cells and that Slug suppresses E-cadherin expression independently of its transcriptional repression activity.

**Slug Represses E-Cadherin Expression at the Post-transcriptional Level in Breast Cancer Cells** Slug is known to repress E-cadherin mRNA expression and promote EMT progression.6) However, Slug expression in MCF7 cells reduced E-cadherin protein level without decreasing its mRNA level. Therefore, we hypothesized that Slug represses E-cadherin protein translation or promotes protein degradation (Fig. 4A). To test the possibility that Slug promotes E-cadherin degradation, we treated Slug-expressing MCF7 cells with the proteasomal inhibitor MG-132 or the lysosomal inhibitor bafilomycin A1 and then analyzed accumulation of E-cadherin (Figs. 4B, C). However, E-cadherin accumulation induced by each inhibitor was not changed in Slug-expressing MCF7 cells compared with the control cells, suggesting that Slug did not increase proteasome- or lysosome-mediated E-cadherin degra-
Similar to Slug-expressing cells, E-cadherin accumulation induced by MG-132 did not increase in FOXA1-depleted MCF7 cells (Fig. 4D). Taken together, these results suggest that Slug suppresses E-cadherin expression probably through repression at the translational level in epithelial breast cancer MCF7 cells.

DISCUSSION

The transcription factor FOXA1 binds to genomic DNA via the forkhead DNA-binding domain and regulates expression of various genes.7) The promoter region of CDH1 has FOXA1-binding sites, and CDH1 expression was shown to be directly induced by FOXA1.20) FOXA1 is also known to act as a transcriptional repressor. In epithelial breast cancer cells, FOXA1 represses expression of genes involved in malignant tumor phenotypes, and depletion of FOXA1 increases cellular motility.15) In prostate cancer cells, FOXA1 binds to the genomic region of SNAI2 and represses its expression.14)

In this study, we showed that FOXA1 induces E-cadherin expression in breast cancer cells. Notably, FOXA1 promoted E-cadherin expression at the mRNA and protein levels in mesenchymal MDA-MB-231 cells, whereas FOXA1 induced E-cadherin expression without affecting its mRNA expression in epithelial MCF7 cells. These results suggest that there is a difference in the mechanisms underlying FOXA1-mediated expression of E-cadherin between epithelial and mesenchymal breast cancer cells. In epithelial breast cancer MCF7 cells, FOXA1-knockdown induced expression of the E-cadherin repressor Slug. Stable expression of Slug in MCF7 cells reduced E-cadherin protein expression without reducing its mRNA expression or promoting its protein degradation. Because the effects of FOXA1 depletion and Slug expression on E-cadherin expression are similar in MCF7 cells, we hypothesize that FOXA1 induces E-cadherin expression primarily through suppression of Slug in epithelial breast cancer cells (Supplementary Fig. S2).

Although Slug is known as a transcriptional repressor of CDH1,6) our present data showed that Slug reduced E-cadherin protein level without reducing its mRNA level in MCF7 cells, suggesting that Slug suppresses E-cadherin expression independently of transcriptional repression in these cells. Because proteasome- or lysosome-mediated E-cadherin degradation was not increased by Slug expression, we primar-
ily hypothesize that Slug inhibits E-cadherin expression at the translational level. Transcriptional repression is mainly caused by microRNAs, which suppress translation by binding to 3'-untranslated regions (UTRs) of target mRNAs. Notably, recent studies have shown that Slug induces expression of microRNA-221 (miR-221) and suppresses E-cadherin protein translation via this microRNA. Although we have not yet analyzed expression of miR-221 in FOXA1-depleted or Slug-expressing MCF7, we speculate that miR-221 is induced by Slug and then suppresses the translation of E-cadherin in these cells. However, our present data showed that E-cadherin mRNA expression was increased, rather than decreased, in FOXA1-depleted or Slug-expressing MCF7 cells, and this phenomenon was not observed in miR-221-expressing MCF7 cells. Therefore, we hypothesize that a feedback mechanism that compensates E-cadherin protein reduction drives E-cadherin mRNA expression in these MCF7 cells. We also have another hypothesis is that Slug induces proteasome- or lysosome-independent E-cadherin protein degradation. To examine the involvement of such proteasome- or lysosome-independent degradation mechanism, E-cadherin protein half-life should be analyzed with the translational inhibitor cycloheximide in FOXA1-depleted or Slug-expressing cells.

Previous studies showed that FOXA1 forms a complex with ERα and histone deacetylase 7 to suppress expression of reprimo gene (RPRM) in breast cancer cells. However, our present results showed that stable expression of FOXA1 in ERα-negative breast cancer MDA-MB-231 cells suppressed Slug expression, suggesting that FOXA1 regulates expression of this gene independently of estrogen receptors. Similarly, although FOXA1 is indispensable for androgen receptor-mediated gene expression, FOXA1 suppresses SNAI2 expression independently of androgen receptor in prostate cancer cells. These results suggest that FOXA1 represses gene expression both dependently and independently of estrogen receptors. Recently, we found that FOXA1 suppresses binding of the transcription factor nuclear factor-κB (NF-κB) to the promoter region of interleukin (IL)-6 gene and represses its expression independently of ERα in breast cancer cells. Therefore, we hypothesize that FOXA1 binds to the promoter region of SNAI2 and suppresses association of an undefined transcription factor for SNAI2 independently of estrogen receptors.

Expression of FOXA1 in MDA-MB-231 cells suppressed Slug expression but not Snail expression (Figs. 1A, B), whereas FOXA1 knockdown increased both Slug and Snail expression in MCF7 cells (Figs. 2A–C), suggesting that Slug and Snail expression is differently regulated by FOXA1. Although the exact mechanism is unclear, we hypothesize that Snail expression is driven by multiple mechanisms, which are insensitive to FOXA1-mediated repression, in MDA-MB-231 cells to maintain strong mesenchymal phenotypes.

In conclusion, our present results showed that FOXA1 suppresses EMT progression probably through suppression of Slug expression in epithelial breast cancer cells. Because FOXA1 is required for proliferation of estrogen-dependent epithelial breast cancer cells, FOXA1 may be a therapeutic...
target for this type of cancer. However, our present results suggest that suppression of FOXA1 can induce EMT progression via Slug induction in epithelial breast cancer. Therefore, dual inhibition of FOXA1 and Slug is expected to suppress both proliferation and EMT progression of epithelial breast cancer cells and may be a promising therapeutic strategy for this type of cancer.

**Acknowledgments** This work was supported in part by Grants-in-Aid for Scientific Research C [Grant numbers 16K08227 (to Noritaka Y.) and 15K07922 (to Naoto Y.)] and Program for Leading Graduate Schools (Leading Graduate School Chiba University Nurture of Creative Research Leaders in Immune System Regulation and Innovative Therapeutics) from the Japanese Ministry of Education, Culture, Sports, Science, and Technology; and Grants from the Hamaguchi Foundation for the Advancement of Biochemistry (to Noritaka Y.) and the Japan Foundation for Applied Enzymology (to Naoto Y.). M.M. and T.H. are Research Assistants of Program for Leading Graduate Schools and Research Fellows of the Japan Society for the Promotion of Science.

**Conflict of Interest** The authors declare no conflict of interest.

**Supplementary Materials** The online version of this article contains supplementary materials.

**REFERENCES**

1) Tam WL, Weinberg RA. The epigenetics of epithelial–mesenchymal plasticity in cancer. Nat. Med., 19, 1438–1449 (2013).
2) De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. _Nat. Rev. Cancer_, **13**, 97–110 (2013).

3) Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, Schwabe RF, Vahdat LT, Altorki NK, Mittal V, Gao D. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. _Nature_, **527**, 472–476 (2015).

4) Zheng X, Carstens JL, Scheible M, Kaye J, Sugimoto H, Wu CC, LeBleu VS, Kalluri R. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. _Nature_, **527**, 525–530 (2015).

5) Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial–mesenchymal transition. _Nat. Rev. Mol. Cell Biol._, **15**, 178–196 (2014).

6) Nieto MA. The snail superfamily of zinc-finger transcription factors. _Nat. Rev. Mol. Cell Biol._, **3**, 155–166 (2002).

7) Bernardo GM, Keri RA. FOXA1: a transcription factor with parallel functions in development and cancer. _Biosci. Rep._, **32**, 113–130 (2012).

8) Kaestner KH. The FoxA factors in organogenesis and differentiation. _Curr. Opin. Genet. Dev._, **20**, 527–532 (2010).

9) Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, Eckhout J, Shao W, Hestermann EV, Geistlinger TR, Fox EA, Silver PA, Brown M. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. _Cell_, **122**, 33–43 (2005).

10) Yamaguchi N, Shibazaki M, Yamada C, Anzai E, Morii M, Nakayama Y, Kuga T, Hashimoto Y, Tomonaga T, Yamaguchi N. Tyrosine phosphorylation of the pioneer transcription factor FoxA1 promotes activation of estrogen signaling. _J. Cell. Biochem._, **118**, 1453–1461 (2017).

11) Bernardo GM, Lozada KL, Miedler JD, Harburg G, Hewitt SC, Mosley JD, Godwin AK, Korach KS, Visvader JE, Kaestner KH, Abdul-Karim FW, Montano MM, Keri RA. FOXA1 is an essential determinant of ERα expression and mammary ductal morphogenesis. _Development_, **137**, 2045–2054 (2010).

12) Yamaguchi N, Ito E, Azuma S, Honma R, Yanagisawa Y, Nishikawa A, Kawamura M, Imai J, Tatsuta K, Inoue J, Semba K, Watanabe S. FoxA1 as a lineage-specific oncogene in luminal type breast cancer. _Biochem. Biophys. Res. Commun._, **365**, 711–717 (2008).

13) Song Y, Washington MK, Crawford HC. Loss of FOXA1 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. _Cancer Res._, **70**, 2115–2125 (2010).

14) Jin HJ, Zhao JC, Ogden I, Bergan RC, Yu J. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. _Cancer Res._, **73**, 3722–3736 (2013).

15) Bernardo GM, Bebek G, Ginther CL, Sizemore ST, Lozada KL, Miedler JD, Anderson LA, Godwin AK, Abdul-Karim FW, Slamon DJ, Keri RA. FOXA1 represses the molecular phenotype of basal breast cancer cells. _Oncogene_, **32**, 554–563 (2013).

16) Thorat MA, Marchio C, Morimiya A, Savage K, Nakshatri H, Reis-Filho JS, Badve S. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. _J. Clin. Pathol._, **61**, 327–332 (2008).

17) Yamaguchi N, Nakayama Y, Yamaguchi N. Down-regulation of Forkhead Box Protein A1 (FOXA1) leads to cancer-stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6. _J. Biol. Chem._, **292**, 8136–8148 (2017).

18) Yamaguchi N, Yuki R, Kubota S, Aoyama K, Kuga T, Hashimoto Y, Tomonaga T, Yamaguchi N. c-Abl-mediated tyrosine phosphorylation of JunB is required for Adriamycin-induced expression of p21. _Biochem. J._, **411**, 87–97 (2008).

19) Aoyama K, Fukumoto Y, Ishibashi K, Kubota S, Morinaga T, Horisue Y, Yuki R, Takahashi A, Nakayama Y, Yamaguchi N. Nucleolar c-Abl-mediated tyrosine phosphorylation induces chromatin structural changes through histone modifications that include H4K16 hypoacetylation. _Exp. Cell Res._, **317**, 2874–2903 (2011).

20) Liu YN, Lee WW, Wang CY, Chao TH, Chen Y, Chen JH. Regulatory mechanisms controlling human E-cadherin gene expression. _Oncogene_, **24**, 8277–8290 (2005).

21) Ye Y, Xiao Y, Wang W, Yearsley K, Gao JX, Shetuni B, Barsky SH. EKra signaling through slug regulates E-cadherin and EMT. _Oncogene_, **29**, 1451–1462 (2010).

22) Shenoy A, Blelloch RH. Regulation of microRNA function in somatic stem cell proliferation and differentiation. _Nat. Rev. Mol. Cell Biol._, **15**, 565–576 (2014).

23) Pan Y, Li J, Zhang Y, Wang N, Liang H, Liu Y, Zhang CY, Zen K, Gu H. Slug-upregulated miR-221 promotes breast cancer progression through suppressing E-cadherin expression. _Sci. Rep._, **6**, 25798 (2016).

24) Malik S, Jiang S, Garee JP, Verdin E, Lee AV, O’Malley BW, Zhang M, Belaguli NS, Oesterreich S. Histone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRM. _Mol. Cell Biol._, **30**, 399–412 (2010).